Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
13-15 January, 2025
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
13-16 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
13-15 January, 2025
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
13-16 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/bms-j-j-bayer-lead-25-000-pharma-layoffs-in-2024-amylyx-fibrogen-kronos-bio-hit-by-trial-failures-cash-crunch
05 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-date-of-third-quarter-2024-results-presentation-302295611.html
03 Oct 2024
// BUSINESSWIRE
12 Sep 2024
// CONTRACT PHARMA
https://www.contractpharma.com//contents/view_breaking-news/2024-09-12/ginkgo-bioworks-introduces-ginkgo-automation-product-line/?widget=listSection
28 Jun 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/medtech/ginkgo-bioworks-lay-many-400-employees
11 May 2024
// Katherine Lewin PRESS RELEASE
https://investors.ginkgobioworks.com/news/news-details/2024/Ginkgo-Bioworks-Reports-First-Quarter-2024-Financial-Results/default.aspx
12 Apr 2024
// BUSINESSWIRE
Details:
The partnership aims to enhance the manufacturing of Novo's medicines for serious chronic diseases, including diabetes and obesity, leveraging Ginkgo's synthetic biology platform for new methods.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Novo Nordisk
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration April 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain
Details : The partnership aims to enhance the manufacturing of Novo's medicines for serious chronic diseases, including diabetes and obesity, leveraging Ginkgo's synthetic biology platform for new methods.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
April 10, 2024
Details:
Through the acquisition, Ginkgo will get access to the Modulus cell therapy platform assets, including their chimeric antigen receptor and switch receptor libraries for solid tumors, autoimmune, etc.
Lead Product(s): CAR-T Cell Therapy
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Modulus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 02, 2024
Lead Product(s) : CAR-T Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Modulus Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Ginkgo Bioworks Acquires Modulus Cell Therapy Platform Assets
Details : Through the acquisition, Ginkgo will get access to the Modulus cell therapy platform assets, including their chimeric antigen receptor and switch receptor libraries for solid tumors, autoimmune, etc.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 02, 2024
Details:
The financing will be used to develop a novel live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Large molecule
Sponsor: Bill & Melinda Gates Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding December 13, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Details : The financing will be used to develop a novel live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 13, 2023
Details:
Under the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Large molecule
Sponsor: Pfizer Inc
Deal Size: $331.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 27, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $331.0 million
Deal Type : Collaboration
Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer
Details : Under the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 27, 2023
Details:
The companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Boehringer Ingelheim GmbH
Deal Size: $406.0 million Upfront Cash: Undisclosed
Deal Type: Partnership May 08, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Boehringer Ingelheim GmbH
Deal Size : $406.0 million
Deal Type : Partnership
Details : The companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
May 08, 2023
Details:
The addition of StrideBio's structure-guided AAV engineering capabilities combined with Ginkgo's already extensive assets make Ginkgo a unique one-stop shop capable of providing R&D services for gene therapy manufacturing across capsid, payload, and cell line optimization.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Cell and Gene therapy
Recipient: StrideBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 05, 2023
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Recipient : StrideBio
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The addition of StrideBio's structure-guided AAV engineering capabilities combined with Ginkgo's already extensive assets make Ginkgo a unique one-stop shop capable of providing R&D services for gene therapy manufacturing across capsid, payload, and cell...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 05, 2023
Details:
Proceeds will support clinical development of the Company’s lead oncology candidate in non-muscle invasive bladder cancer and accelerate platform discovery.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Large molecule
Recipient: Prokarium
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Prokarium
Deal Size : $30.0 million
Deal Type : Financing
Details : Proceeds will support clinical development of the Company’s lead oncology candidate in non-muscle invasive bladder cancer and accelerate platform discovery.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 09, 2023
Details:
Bactofection, the process of transferring genetic material into a mammalian cell via a bacterium, is an alternative gene delivery system that could deliver therapeutic agents to a patient in RNA-based therapy.
Lead Product(s): RNA-based Therapy
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Large molecule
Recipient: Prokarium
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 09, 2023
Details : Bactofection, the process of transferring genetic material into a mammalian cell via a bacterium, is an alternative gene delivery system that could deliver therapeutic agents to a patient in RNA-based therapy.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 09, 2023
Details:
CircRNAs (circular RNA based therapy) represent an emerging, powerful mechanism for delivering therapeutics and vaccines due to their protein-coding potential and improved stability in comparison to their linear mRNA counterparts.
Lead Product(s): Circular RNA-based Therapy
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Large molecule
Recipient: Esperovax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 05, 2023
Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics
Details : CircRNAs (circular RNA based therapy) represent an emerging, powerful mechanism for delivering therapeutics and vaccines due to their protein-coding potential and improved stability in comparison to their linear mRNA counterparts.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 05, 2023
Details:
Circularis platform will give Ginkgo the ability to rapidly identify context-specific promoters for cell therapy and circular RNA-based therapeutic applications, such as those that modulate gene expression in the tumor microenvironment.
Lead Product(s): Circular RNA-based Therapeutic
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Large molecule
Recipient: Circularis Biotechnologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 04, 2022
Lead Product(s) : Circular RNA-based Therapeutic
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : Circularis Biotechnologies
Deal Size : Undisclosed
Deal Type : Acquisition
Ginkgo Bioworks Acquires Circularis to Strengthen Capabilities in Cell and Gene Therapy
Details : Circularis platform will give Ginkgo the ability to rapidly identify context-specific promoters for cell therapy and circular RNA-based therapeutic applications, such as those that modulate gene expression in the tumor microenvironment.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 04, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?